Introduction

The ankle-brachial index (ABI) is reported to be a good marker for atherosclerosis and an ABI <0.9 is useful in the diagnosis of peripheral artery occlusive disease (PAOD) [1,2]. In addition, an ABI ≥1.3 is considered to indicate medial artery calcification (MAC) [3]. High prevalence of PAOD and increased MAC are frequently noted in patients with chronic kidney disease (CKD) [4,5], which may through some processes including vascular calcification, inflammatory and coagulation pathways alterations, oxidative stress, malnutrition and infection [6-8]. Moreover, either abnormally low or high ABIs can predict overall and cardiovascular mortality in patients with chronic renal failure [9-11]. However, the mechanisms responsible for the association are not fully known.

Recent studies in hypertensive patients and in general population reported abnormally low and high ABIs were independently associated with increased left ventricular mass [12,13]. Abnormally low and high ABIs are affected by or linked to various risk factors for left ventricular hypertrophy (LVH), such as arterial stiffness, hypertension and coexisting atherosclerosis [14,15]. LVH is frequently encountered in patients with CKD because of pressure and volume overload, increased arterial stiffness, anemia, inflammatory status, protein malnutrition and sodium/water retention, which were also key causes for atherosclerosis in this population [16-19]. LVH and peripheral artery disease are common cardiovascular complications in CKD patients, in whom there may be a close and cause-effect relationship. However, there are limited studies to evaluate the association between abnormal ABI and left ventricular mass index (LVMI) in CKD patients, whom frequently have many atherosclerotic risk factors and increased left ventricular mass. Accordingly, the aim of this study is to assess whether there is an independent association between abnormal ABI and increased LVMI in patients with CKD stages 3–5.

Subjects and Methods

Study Patients and Design

The study was conducted in a regional hospital in southern Taiwan. We consecutively enrolled patients with CKD of stages 3 to 5 [20] from our Outpatient Department of Internal Medicine from July 2009 to February 2010. Patients with atrial fibrillation, inadequate image visualization and ABI <0.9 in one leg and ABI...
A total of 684 patients (mean age 65.5 ± 12.5 years, 401 males/283 females) were included.

**Ethics Statement**

The study protocol was approved by the institutional review board of the Kaohsiung Medical University Hospital (KMUH-IRB-20120058). Informed consents have been obtained in written form from patients and all clinical investigation was conducted according to the principles expressed in the Declaration of Helsinki. The patients gave consent for the publication of the clinical details.

**Evaluation of cardiac structure and function**

The echocardiographic examination was performed by one experienced cardiologist with a VIVID 7 (General Electric Medical Systems, Horten, Norway), with the participant respiring quietly in the left decubitus position. The cardiologist was blind to the other data. Two-dimensional and two-dimensionally guided M-mode images were recorded from the standardized views. The echocardiographic measurements included left ventricular internal diameter in diastole (LVIDd), left ventricular posterior wall thickness in diastole (LVPWTd), interventricular septal wall thickness in diastole (IVSTd), E-wave deceleration time, peak early transmural filling wave velocity (E) and peak late transmural filling wave velocity (A).

**Table 1. Comparison of clinical and echocardiographic characteristics between patients with normal and abnormal ABI.**

| Characteristics                        | ABI ≥0.9 to <1.3 (n = 556) | ABI <0.9 (n = 62) | ABI ≥1.3 (n = 66) |
|----------------------------------------|-----------------------------|-------------------|-------------------|
| Age (year)                             | 64.6 ± 12.4                 | 75.3 ± 9.6**      | 63.6 ± 12.1       |
| Male gender (%)                        | 57.7                        | 61.3              | 63.6              |
| Smoking history (%)                    | 33.7                        | 46.7              | 31.8              |
| Diabetes mellitus (%)                  | 35.3                        | 61.3**            | 54.5              |
| Hypertension (%)                       | 76.3                        | 90.3              | 84.8              |
| Coronary artery disease (%)            | 15.2                        | 35.5**            | 21.2              |
| Cerebrovascular disease (%)            | 8.8                         | 28.1**            | 8.2               |
| Stage of CKD                           |                             |                   |                   |
| Stage 3 (%)                            | 76.1                        | 59.7*             | 59.1*             |
| Stage 4 (%)                            | 12.6                        | 22.6              | 13.6              |
| Stage 5 (%)                            | 11.3                        | 17.7              | 27.3              |
| Systolic blood pressure (mmHg)         | 140.7 ± 22.4                | 144.1 ± 21.5      | 138.6 ± 19.3      |
| Diastolic blood pressure (mmHg)        | 79.2 ± 12.8                 | 73.9 ± 11.7**     | 76.8 ± 12.6       |
| Pulse pressure (mmHg)                  | 61.6 ± 15.1                 | 70.2 ± 17.3**     | 61.8 ± 12.5       |
| Body mass index (kg/m2)                | 25.7 ± 4.0                  | 24.3 ± 3.3        | 26.9 ± 5.1        |
| Laboratory parameters                  |                             |                   |                   |
| Albumin (g/dL)                         | 4.12 ± 0.4                  | 3.90 ± 0.50*      | 4.08 ± 0.40       |
| Fasting glucose (mg/dL)                | 113.6 ± 39.4                | 135.2 ± 67.4*     | 127.3 ± 53.7      |
| Triglyceride (mg/dL)                   | 126 (88–187)                | 127 (86–175)      | 117 (87.75–175.25)|
| Total cholesterol (mg/dL)              | 189.5 ± 40.2                | 192.2 ± 47.1      | 186.4 ± 37.0      |
| Hematocrit (%)                         | 38.5 ± 6.0                  | 35.2 ± 6.2**      | 36.0 ± 6.5*       |
| eGFR (mL/min/1.73 m2)                  | 408 ± 16.1                  | 33.9 ± 15.4       | 33.3 ± 18.6       |
| Uric acid (mg/dL)                      | 7.4 ± 2.1                   | 7.8 ± 2.6         | 7.7 ± 2.2         |
| Proteinuria (%)                        | 53.5                        | 71.4              | 77.3              |
| Medications                            |                             |                   |                   |
| Aspirin use (%)                        | 18.3                        | 20.0              | 21.4              |
| ACEI and/or ARB use (%)                | 61.9                        | 75.4*             | 53.4              |
| Non-ACEI/ARB antihypertensive drug use | 72.1                        | 83.9              | 77.3              |
| Statin use (%)                         | 21.9                        | 25.0              | 18.9              |
| Echocardiographic data                 |                             |                   |                   |
| LVMI (g/m²)                            | 129.6 ± 45.7                | 150.3 ± 58.1*     | 154.7 ± 50.3**    |
| LVH (%)                                | 65.3                        | 74.2              | 83.3              |
| LVEF (%)                               | 62.5 ± 13.7                 | 58.7 ± 16.7       | 62.0 ± 13.5       |
| E-wave deceleration time (ms)          | 211.9 ± 67.6                | 215.9 ± 85.5      | 225.3 ± 72.5      |
| E/A                                    | 0.95 ± 0.54                 | 0.99 ± 0.46       | 0.95 ± 0.49       |

Abbreviations. ABI, ankle-brachial index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; LVMI, left ventricular mass index; LVIDd, left ventricular internal diameter; LVPWTd, left ventricular posterior wall thickness in diastole; IVSTd, interventricular septal wall thickness in diastole; LVEF, left ventricular ejection fraction; E, peak early transmural filling wave velocity; A, peak late transmural filling wave velocity.

*P < 0.05, **P < 0.001 compared with ABI of ≥0.9 to <1.3 in both legs.

doi:10.1371/journal.pone.0044732.t001
Left ventricular systolic function was assessed by left ventricular ejection fraction (LVEF). Left ventricular mass was calculated using Devereux-modified method, i.e. left ventricular mass = 1.04 \[(IVSTd + LVIDd + LVPWTd) ^ 3 - LVIDd ^ 3\] – 13.6g [21]. LVMI was calculated by dividing left ventricular mass by body surface area. LVH was defined as suggested by the American Society of Echocardiography/European Society of Echocardiography chamber quantification guidelines [22]. Left ventricular relative wall thickness (LVRWT) was calculated as the ratio of 2 × LVPWTd / LVIDd. Cardiac remodeling was defined as LVRWT more than 0.42 without LVH. Concentric LVH was defined as LVMI more than 115 g/m^2 in men and more than 95 g/m^2 in women, with LVRWT more than 0.42; eccentric LVH was defined as LVMI more than 115 g/m^2 in men and more than 95 g/m^2 in women, with LVRWT less than 0.42. In addition, thirty patients were randomly selected for evaluation of the interobserver variability of left ventricular mass measurement by 2 independent observers. Mean percent error was calculated as the absolute difference divided by the average of the two observations. The interobserver mean percent error for left ventricular mass measurement in this study was 9.8±5.8%.

### Table 2. Comparison of clinical and echocardiographic characteristics between patients without and with LVH.

| Characteristics | Non-LVH (n = 302) | LVH (n = 382) |
|-----------------|------------------|--------------|
| ABI             |                  |              |
| ≥0.9 to<1.3     | 87.7             | 78.2*        |
| <0.9 in either leg | 7.3              | 9.9          |
| ≥1.3 in either leg | 5.0              | 11.9*        |
| Age (year)      | 63.8±12.2        | 66.3±12.6*   |
| Male gender (%) | 69.1             | 53.7**       |
| Smoking history (%) | 37.5            | 30.5         |
| Diabetes mellitus (%) | 39.1         | 39.7         |
| Hypertension (%) | 75.9             | 79.5         |
| Coronary artery disease (%) | 17.4 | 17.8 |
| Cerebrovascular disease (%) | 12.1 | 9.7 |
| Stage of CKD    |                  |              |
| Stage 3 (%)     | 74.1             | 72.4         |
| Stage 4 (%)     | 16.8             | 12.1         |
| Stage 5 (%)     | 9.1              | 15.5*        |
| Systolic blood pressure (mmHg) | 136.2±19.7 | 143.0±22.7** |
| Diastolic blood pressure (mmHg) | 78.1±11.5 | 78.6±13.3 |
| Pulse pressure (mmHg) | 58.1±13.7 | 64.4±15.6** |
| Body mass index (kg/m2) | 25.0±3.8 | 26.0±4.2* |
| Laboratory parameters |                  |              |
| Albumin (g/dL) | 4.19±0.34        | 4.03±0.45** |
| Fasting glucose (mg/dL) | 120.0±50.3 | 115.2±41.1 |
| Triglyceride (mg/dL) | 118.5 (88–189.5) | 132 (88–182) |
| Total cholesterol (mg/dL) | 188.5±38.7 | 189.9±41.4 |
| Hematocrit (%) | 39.1±5.9         | 37.4±6.2*    |
| eGFR (mL/min/1.73 m2) | 41.4±16.0 | 38.6±16.8* |
| Uric acid (mg/dL) | 7.4±2.1         | 7.5±2.1      |
| Proteinuria (%) | 50.8             | 64.6*        |
| Medications |                  |              |
| Aspirin use (%) | 17.0             | 21.0         |
| ACEI and/or ARB use (%) | 62.8       | 62.2         |
| Non-ACEI/ARB antihypertensive drug use (%) | 66.8 | 76.9* |
| Statin use (%) | 20.8             | 22.4         |
| Echocardiographic data |              |              |
| LVMI (g/m^2) | 89.2±18.2        | 155.1±43.1** |
| LVEF (%) | 65.8±11.6        | 60.4±14.7** |
| E-wave deceleration time (ms) | 214.7±64.4 | 213.0±72.3 |
| E/A | 0.95±0.57        | 0.96±0.51    |

*P<0.05, **P<0.001 compared with patients without LVH. Abbreviations are the same as in Table 1.

doi:10.1371/journal.pone.0044732.t002
Assessment of ABI

The values of ABI were measured by using an ABI-form device (VP1000; Colin Co. Ltd., Komaki, Japan), which automatically and simultaneously measured blood pressures in both arms and ankles using an oscillometric method [23–25]. The ABI was calculated by the ratio of the ankle systolic blood pressure divided by the higher systolic blood pressure of the arms. The ABI measurement was done once in each patient. Patients were classified into ABI <0.9 in either leg, ≥0.9 to <1.3 in both legs and ≥1.3 in either leg.

Collection of demographic, medical, and laboratory data

Demographic and medical data including age, gender, smoking history (ever versus never) and comorbid conditions were obtained from medical records or interviews with patients. The body mass index (BMI) was calculated as the ratio of weight in kilograms divided by square of height in meters. Laboratory data were measured from fasting blood samples using an autoanalyzer (Roche Diagnostics GmbH, D-68290 Mannheim COBAS Integra 400). Serum creatinine was measured by the compensated Jaffe’s (kinetic alkaline picrate) method in a Roche/Integra 400 Analyzer (Roche Diagnostics, Mannheim, Germany) using a calibrator traceable to isotope-dilution mass spectrometry [26]. The value of estimated glomerular filtration rate (eGFR) was calculated using the 4-variable equation in the Modification of Diet in Renal Disease (MDRD) study [27]. Proteinuria was examined by dipsticks (Hema-Combistix, Bayer Diagnostics). A test result of 1+ or more was defined as positive. Blood and urine samples were obtained within 1 month of enrollment. In addition, information regarding patient medications including aspirin, angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), non-ACEI/ARB antihypertensive drugs and HMG-CoA reductase inhibitors (statins) during the study period was obtained from medical records.

Statistical analysis

Statistical analysis was performed using SPSS 15.0 for windows (SPSS Inc. Chicago, USA). Data are expressed as percentages, mean ± standard deviation or median (25th–75th percentile) for triglyceride. The differences between groups were checked by Chi-square test for categorical variables or by independent t-test for continuous variables. The relationship between two continuous variables was assessed by a bivariate correlation method (Pearson’s correlation). Multiple linear and logistic regression analyses were used to identify the factors associated with LVMI and abnormal ABI, respectively. Significant variables in univariate analysis were selected for multivariate analysis. A difference was considered significant if the P value was less than 0.05.

Abnormal ABI and LVMI in CKD

Table 3. ABI category in different left ventricular geometry.

| Characteristics | Normal (n = 244) | Concentric remodeling (n = 58) | Eccentric LVH (n = 284) | Concentric LVH (n = 98) | P |
|-----------------|-----------------|-----------------|----------------|----------------|---|
| ABI ≥0.9 to <1.3 (%) | 87.7 | 87.7 | 80.4* | 74.2* | 0.001 |
| <0.9 in either leg (%) | 5.8 | 10.8 | 9.6 | 10.4 | 0.041 |
| ≥1.3 in either leg (%) | 6.5 | 1.5 | 10.0 | 15.3 | 0.018 |

*P<0.05, **P<0.001 compared with patients with normal left ventricular geometry. Abbreviations are the same as in Table 1.

doi:10.1371/journal.pone.0044732.t003

Results

The mean age of the 684 patients was 65.5±12.5 years. The prevalences of ABI <0.9 and ≥1.3 were 9.1% and 9.6%, respectively. The differences between patients with normal and abnormal ABI were shown in Table 1. Compared with patients with normal ABI, patients with ABI <0.9 were found to have an older age, higher prevalence of diabetes mellitus (DM), hypertension, coronary artery disease and cerebrovascular disease, lower prevalence of stage 3 CKD, lower diastolic blood pressure, higher pulse pressure, higher BMI, lower serum albumin, lower fasting glucose, lower hematocrit, lower eGFR, higher percentage of ACEI and/or ARB and non-ACEI/ARB antihypertensive drug use and higher LVMI (P=0.009). In addition, compared with patients with normal ABI, patients with ABI ≥1.3 were found to have higher prevalence of DM, lower prevalence of stage 3 CKD, lower hematocrit, lower eGFR, higher LVMI (P<0.001) and higher prevalence of LVH (P=0.009). The LVMI values in ABI ≥0.9 to <1.3, <0.9 and ≥1.3 were 129.6±45.7, 150.3±58.1 and 154.7±50.3 g/m², respectively. Additionally, the prevalences of LVH in these patients were 65.3%, 74.2% and 83.3%, respectively.

The comparison of clinical and echocardiographic characteristics between patients with and without LVH was shown in Table 2. Compared with patients without LVH, patients with LVH had lower prevalence of normal ABI, higher prevalence of ABI ≥1.3, an older age, a lower percentage of male patients, higher prevalence of stage 5 CKD, higher systolic blood pressure, wider pulse pressure, higher BMI, lower albumin, lower hematocrit, lower eGFR, higher prevalence of proteinuria, higher percentage of having received non-ACEI and/or ARB therapy, higher LVMI and lower LVEF. In addition, Table 3 showed the percentage of ABI category in different left ventricular geometry.

Table 4 showed the determinants of LVMI in our study patients. The LVMI correlated positively with ABI <0.9 and ≥1.3 (versus ABI ≥0.9 to <1.3), systolic blood pressure, pulse pressure, BMI, non-ACEI/ARB antihypertensive drug use and E/A, but negatively with serum albumin level, total cholesterol, hematocrit, eGFR and LVEF. Further forward multivariate analysis showed that increased LVMI was correlated with ABI <0.9 (β = 0.099, P=0.004), ABI ≥1.3 (β = 0.143, P<0.001), increased systolic blood pressure, increased BMI and decreased LVEF.

Table 5 shows the determinants of abnormal ABI (ABI <0.9 or ≥1.3) in study patients. In the univariate analysis, abnormal ABI was found to be significantly associated with increased age, a history of DM, hypertension, coronary artery disease, and cerebrovascular disease, decreased diastolic blood pressure, increased pulse pressure, decreased albumin, increased fasting glucose, decreased hematocrit, decreased eGFR, proteinuria and increased LVMI. In the forward multivariate analysis, a history of coronary artery disease, increased fasting glucose, decreased
hematocrit and increased LVMI (odds ratio [OR], 1.017; 95% confidence interval [CI], 1.002 to 1.033; \(P=0.031\)) were independent risk factors for abnormal ABI.

There were several risk factors which affected ABI, LVMI, and CKD status like DM and hypertension. We performed another analysis to examine the inter-relationship between these factors. The interaction between DM and abnormal ABI on LVH was statistically significant (OR, 2.410; 95% CI, 1.294 to 4.488; \(P=0.006\)). Similarly, the interaction between hypertension and abnormal ABI on LVH was also statistically significant (OR, 2.033; 95% CI, 1.246 to 3.318; \(P=0.005\)).

### Discussion

Previous studies reported a U-shaped relationship between ABI values and cardiovascular events in various populations [10,28,29]. However, the mechanisms responsible for the association are not fully known. In the present study, we evaluated the association of abnormal ABI with LVMI in CKD stage 3–5 patients. We found that either abnormally low or high ABI was independently associated with increased LVMI.

The ABI is a simple, non-invasive and reliable diagnostic tool for peripheral artery disease. An ABI \(<0.9\) have not only been established as a reliable diagnostic marker for PAOD with high sensitivity and specificity, but also a strong predictor for overall and cardiovascular mortality in patients with chronic renal failure [9–11]. PAOD and LVH are highly prevalent in CKD patients [5,30]. Many factors including pressure overload, renal anemia, malnutrition and inflammatory status were not only main causes for development of LVH, but also for atherosclerosis and increased arterial stiffness in patients with CKD [30,31]. Previous studies demonstrated that the ABI value in the LVH group was significantly lower than that in the non-LVH group.

### Table 4. Determinants of LVMI in study patients.

| Parameter                        | Univariate            | Multivariate (Forward) |
|----------------------------------|-----------------------|------------------------|
|                                  | Standardized coefficient \(\beta\) | \(P\) | Standardized coefficient \(\beta\) | \(P\) |
| ABI (versus \(\geq 0.9\) to \(< 1.3\)) | Reference             | Reference             |
| \(< 0.9\) in either leg | 0.123                 | 0.001                  | 0.099                  | 0.004             |
| \(\geq 1.3\) in either leg  | 0.154                 | \(< 0.001\)            | 0.143                  | \(< 0.001\)        |
| Age (per 1 year)                 | 0.062                 | 0.103                  | -                      | -                  |
| Male versus female              | 0.058                 | 0.130                  | -                      | -                  |
| Smoking (ever versus never)      | 0.077                 | 0.244                  | -                      | -                  |
| Diabetes mellitus               | 0.028                 | 0.467                  | -                      | -                  |
| Hypertension                     | 0.044                 | 0.249                  | -                      | -                  |
| Coronary artery disease          | 0.001                 | 0.987                  | -                      | -                  |
| Cerebrovascular disease          | 0.016                 | 0.684                  | -                      | -                  |
| Systolic blood pressure (per 1 mmHg) | 0.165               | \(< 0.001\)            | 0.201                  | \(< 0.001\)        |
| Diastolic blood pressure (per 1 mmHg) | 0.074               | 0.053                  | -                      | -                  |
| Pulse pressure (per 1 mmHg)      | 0.176                 | \(< 0.001\)            | -                      | -                  |
| Body mass index (per 1 kg/m2)    | 0.097                 | 0.011                  | 0.137                  | \(< 0.001\)        |
| Laboratory parameters            |                       |                        |                        |                    |
| Albumin (per 1 g/dL)             | \(-0.294\)            | \(<0.001\)            | -                      | -                  |
| Fasting glucose (per 1 mg/dL)    | \(-0.060\)            | 0.166                  | -                      | -                  |
| Triglyceride (log per 1 mg/dL)   | \(-0.056\)            | 0.175                  | -                      | -                  |
| Total cholesterol (per 1 mg/dL)  | \(-0.090\)            | 0.029                  | -                      | -                  |
| Hematocrit (per 1%)              | \(-0.119\)            | 0.003                  | -                      | -                  |
| eGFR (per 1 mL/min/1.73 m2)       | \(-0.140\)            | \(<0.001\)            | -                      | -                  |
| Uric acid (per 1 mg/dL)          | 0.033                 | 0.446                  | -                      | -                  |
| Laboratory parameters            | 0.174                 | 0.010                  | -                      | -                  |
| Medications                      |                       |                        |                        |                    |
| Aspirin use                      | 0.147                 | 0.073                  | -                      | -                  |
| ACEI and/or ARB use              | 0.017                 | 0.681                  | -                      | -                  |
| Non-ACEI/ARB antihypertensive drug use | 0.088             | 0.022                  | -                      | -                  |
| Statin use                       | \(-0.029\)            | 0.497                  | -                      | -                  |
| Echocardiographic data           |                       |                        |                        |                    |
| LVEF (per 1%)                    | \(-0.358\)            | \(<0.001\)            | \(-0.375\)            | \(<0.001\)        |
| E-wave deceleration time (per 1 ms) | \(-0.037\)            | 0.337                  | -                      | -                  |
| E/A (per 1)                      | 0.079                 | 0.040                  | -                      | -                  |

Values expressed as standardized coefficient \(\beta\). Abbreviations are the same as in Table 1.

doi:10.1371/journal.pone.0044732.t004
Atherosclerosis directly caused a decrease in blood perfusion in the lower extremities and an increase in arterial wall stiffness, contributing to decreasing ABI and arterial distensibility, and then final progressed to LVH [5,34,35]. Reversely, LVH caused left ventricular systolic and diastolic dysfunction and a decrease in cardiac output, which further deteriorated blood perfusion of the extremities and promoted the progression of peripheral arterial disease and decrease of ABI. Our study also consistently revealed there was a higher LVH prevalence and higher LVMI value in patients with ABI.

Falsely elevated pressures or incompressible arteries at ankle level are common among patients with extensive vascular calcification of the lower extremities, which may occur in those with diabetes or renal insufficiency [3,5]. The abnormally high ABI value or incompressible arteries had been interpreted as the presence of MAC [3]. Patients having abnormally high ABI also had poor prognosis for all-cause and cardiovascular mortality in general population and also in chronic renal failure patients [10,11,28,29]. In rodent studies, experimentally induced MAC resulted in greater arterial stiffness and left ventricular mass due to the amount of vascular calcium content. The correlation between MAC and left ventricular mass persistently existed independently of presence or absence of change in mean arterial pressure or arterial diameter, suggesting that MAC might lead to greater left ventricular mass through nonatherosclerotic pathways [15]. Consistent with the experimental model, Ix JH et al. [13] evaluated the association between high ABI and LVMI in 4972 MESA (multi-Ethic Study of atherosclerosis) participants without clinical cardiovascular disease. They found either abnormally low or high ABI was significantly associated with greater LVMI. Besides, they also found that the association between high ABI and LVMI is not attenuated with adjustment of markers of subclinical atherosclerosis, such as common and internal carotid intima media thickness and natural log-transformed coronary artery calcification [13]. Our study showed there was a higher LVH prevalence and

| Parameter | Univariate | Multivariate (Forward) |
|-----------|------------|------------------------|
| OR (95% CI) | P | OR (95% CI) | P |
| Age (per 1 year) | 1.033 (1.016–1.050) | <0.001 | - | - |
| Male versus female | 1.220 (0.822–1.812) | 0.324 | - | - |
| Smoking (ever versus never) | 1.199 (0.579–2.482) | 0.625 | - | - |
| Diabetes mellitus | 2.517 (1.701–3.723) | <0.001 | - | - |
| Hypertension | 2.179 (1.246–3.812) | 0.006 | - | - |
| Coronary artery disease | 2.175 (1.387–3.412) | 0.001 | 5.854 (1.635–20.953) | 0.007 |
| Cerebrovascular disease | 2.232 (1.272–3.917) | 0.005 | - | - |
| Systolic blood pressure (per 1 mmHg) | 1.001 (0.992–1.010) | 0.795 | - | - |
| Diastolic blood pressure (per 1 mmHg) | 0.975 (0.960–0.991) | 0.003 | - | - |
| Pulse pressure (per 1 mmHg) | 1.018 (1.006–1.031) | 0.004 | - | - |
| Body mass index (per 1 kg/m2) | 0.996 (0.950–1.045) | 0.877 | - | - |
| Laboratory parameters | | | |
| Albumin (per 1 g/dL) | 0.527 (0.310–0.896) | 0.018 | - | - |
| Fasting glucose (per 1 mg/dL) | 1.007 (1.003–1.012) | 0.001 | 1.010 (1.001–1.019) | 0.026 |
| Triglyceride (log per 1 mg/dL) | 0.782 (0.320–1.909) | 0.589 | - | - |
| Total cholesterol (per 1 mg/dL) | 1.000 (0.995–1.005) | 0.919 | - | - |
| Hematocrit (per 1%) | 0.926 (0.895–0.957) | <0.001 | 0.916 (0.855–0.980) | 0.011 |
| eGFR (per 1 mL/min/1.73 m2) | 0.975 (0.964–0.986) | <0.001 | - | - |
| Uric acid (per 1 mg/dL) | 1.078 (0.976–1.191) | 0.139 | - | - |
| Proteinuria | 2.606 (1.162–5.845) | 0.020 | - | - |
| Medications | | | |
| Aspirin use | 1.178 (0.399–3.484) | 0.766 | - | - |
| ACEI and/or ARB use | 1.109 (0.727–1.694) | 0.631 | - | - |
| Non-ACEI/ARB antihypertensive drug use | 1.593 (0.991–2.560) | 0.055 | - | - |
| Statin use | 1.002 (0.599–1.877) | 0.993 | - | - |
| Echocardiographic data | | | |
| LVMI (per 1 g/m2) | 1.009 (1.005–1.013) | <0.001 | 1.017 (1.002–1.033) | 0.031 |
| LVEF (per 1%) | 0.990 (0.977–1.003) | 0.126 | - | - |
| E-wave deceleration time (per 1 ms) | 1.002 (0.999–1.005) | 0.196 | - | - |
| E/A (per 1) | 1.045 (0.730–1.496) | 0.810 | - | - |

Values expressed as odds ratio (OR) and 95% confidence interval (CI). Abbreviations are the same as in Table 1.

doi:10.1371/journal.pone.0044732.t005

Table 5. Determinants of abnormal ABI (ABI <0.9 or ≥1.3) in study patients.
higher LVMI value in patients with ABI ≥ 1.3 and high ABI was independently associated with increased LVMI. Hence, higher left ventricular mass might play a role between high ABI and poor cardiovascular prognosis.

Cardiovascular disease is the leading cause of morbidity and mortality in patients with CKD, presumably due to accumulation of risk factors for LVH and atherosclerosis [36,37]. Previous studies demonstrated that diabetes, renal anemia, inflammatory status, protein malnutrition and hypertension played roles in the development of LVH and peripheral artery disease in CKD patients [4,10,19]. In our study, compared with normal ABI, abnormally low and high ABIs had several factors of increased risk for LVH, such as higher prevalence of DM, hypertension, coronary artery disease and cerebrovascular disease, more advanced CKD stage, higher pulse pressure, lower serum albumin and lower hematocrit. Even after adjustment for these factors, abnormally low and high ABIs were still independently associated with higher LVMI.

Our results demonstrated that abnormally low and high ABIs were significantly correlated with increased LVMI in patients with CKD stages 3–5. Future studies are required to determine whether increased LVMI is a causal intermediary between abnormal ABI and adverse cardiovascular outcomes in CKD.

Author Contributions

Conceived and designed the experiments: HMS SCC. Performed the experiments: HMS THL PCH WHL SCC CSL. Analyzed the data: SCC. Contributed reagents/materials/analysis tools: HMS THL PCH WHL SCC CSL. Wrote the paper: HMS SCC. Critical revision: WCV WTL SHS.

References

1. Fowkes FG, Housley E, Cavood EH, Macintyre CG, Ruckley CV, et al. (1991) Ethanol-rich alcohol study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20:384–392.

2. Hasimui B, Li J, Nakayama T, Yu J, Yang J, et al. (2006) Ankle brachial index as a marker of atherosclerosis in chinese patients with high cardiovascular risk. Hypertens Res 29:23–28.

3. Orchard TJ, Strainde DE Jr (1995) Assessment of peripheral vascular disease in diabetes. Report and recommendations of an international workshop sponsored by the American heart association and the American diabetics association 18–20 September 1992, new orleans, Louisiana. Diabetes Care 16:1199–1209.

4. de Vinkena SG, Ortega M, Martinez P, Goicoechea M, Campdera FG, et al. (2002) Subclinical peripheral arterial disease in patients with chronic kidney disease: Prevalence and related risk factors. Kidney Int Suppl 67:844–47.

5. Leskenin Y, Salenius JP, Lihimaki T, Huhula H, Saha H (2002) The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure. Requirements for diagnostics. Am J Kidney Dis 40:472–479.

6. O’Hare A, Johansen K (2001) Lower-extremity peripheral arterial disease among patients with end-stage renal disease. J Am Soc Nephrol 12:2038–2047.

7. O’Hare AM, Hsu CY, Barchetti P, Johansen KL (2002) Peripheral vascular disease risk factors among patients undergoing hemodialysis. J Am Soc Nephrol 13:497–503.

8. Webb AT, Franks PJ, Reaveley DA, Greenhalgh RM, Brown EA (1993) Relationship of high and low ankle brachial index to all-cause and cardiovascular mortality: The strong heart study. Circulation 109:733–738.

9. Guerrero A, Montes R, Munoz-Terol J, Gil-Peralta A, Toro J, et al. (2006) Ankle–brachial blood pressure index predicts all-cause and cardiovascular mortality in hemodialysis patients. J Am Soc Nephrol 17:1591–1596.

10. O’Hare AM, Hsu CY, Barchetti P, Johansen KL, et al. (2010) Ankle brachial index as a predictor for mortality in patients with chronic kidney disease and undergoing haemodialysis. Nephrology (Carlton) 15:294–299.

11. Chen SC, Chang JM, Hwang SJ, Tsai JC, Liu WC, et al. (2010) Ankle brachial index as a predictor for mortality in patients with chronic kidney disease. J Am Soc Nephrol 21:461–470.

12. Albuquerque PF, Albuquerque PH, Albuquerque GO, Servantes DM, Carvalho SM, et al. (2012) Ankle-brachial index and ventricular hypertrophy in arterial hypertensive. Arch Bras Cardiol 98:84–86.

13. Is JH, Kart R, Peralta CA, de Boer IH, Allison MA, et al. (2010) A high ankle brachial index is associated with greater left ventricular mass in multi-ethnic study of atherosclerosis. J Am Coll Cardiol 55:342–349.

14. Aboyans V, Ho E, Dennenberg JO, Ho LA, Natajuran L, et al. (2008) The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in nondiabetic and nonobese diabetic subjects. J Vasc Surg 48:1197–1203.

15. Niederhofer N, Laraduit-Ipodiadou E, Giannelli P, Devies C, Pescliche R, et al. (1997) Calciumification of medial elastic fibers and aortic elasticity. Hypertension 29:999–1006.

16. Chen SC, Chang JM, Liu WC, Su HM, Chen CY, et al. (2009) Determinants of peripheral arterial stiffness in patients with chronic kidney disease in southern taiwan. Kaohsiung J Med Sci 25:366–373.

17. Chen SC, Chang JM, Liu WC, Huang JC, Tsai JC, et al. (2012) Arterial stiffness in patients with chronic kidney disease. Am J Med Sci 343:109–113.

18. O’Hare AM, Glidden DV, Fox CS, Hsu CY (2004) High prevalence of peripheral arterial disease in persons with renal insufficiency: Results from the national health and nutrition examination survey 1999–2000. Circulation 109:320–325.

19. Levey AS, Coresh J, Bolton K, Callistone B, Harvey KS, et al. (2002) Initiative KDQOI. K/d-out clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39:81–260.

20. Deverreux RB, Alonso DR, Lutas EM, Goffleib GJ, Campo E, et al. (1986) Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 57:450–458.

21. Lang RM, Bierig M, Deverreux RB, Lachampam FA, Foster E, et al. (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 18:1440–1463.

22. Tomiyama H, Yamashina A, Arai T, Hirose K, Koji Y, et al. (2003) Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement-a survey of 12517 subjects. Atherosclerosis 166:303–309.

23. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, et al. (2002) Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25:539–564.

24. Yokoyama H, Shoji T, Kimoto E, Shinohara K, Tanaka S, et al. (2003) Pulse wave velocity in lower-limb arteries among patients with peripheral arterial disease. J Atheroscler Thromb 10:253–258.

25. Vickery S, Stevens PE, Dalton RN, van Leute F, Lamb EF (2006) Does the id-mt traceable mdt equation work and is it suitable for use with compensated jaffe and enzymatic creatinine assays? Nephrol Dial Transplant 21:2439–2445.

26. Levey AS, Bosco JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470.

27. O’Hare AM, Katz R, Shlipak MG, Cashman M, Newman AB (2006) Mortality and cardiovascular risk across the ankle-arm index spectrum: Results from the cardiovascular health study. Circulation 113:388–393.

28. Reimann HE, Lindsay RS, McDermott MM, Deverreux RB, Jones KL, et al. (2006) Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: The strong heart study. Circulation 109:733–739.

29. Levin A, Singer J, Thompson CR, Ross H, Lewis M (1996) Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347–354.

30. Levin A, Thompson CR, Ether J, Carlile EJ, Tobe S, et al. (1999) Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34:125–134.

31. Deverreux RB, Reichtek N (1972) Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55:613–618.

32. Fu W, Ye C, Mei C, Rong S, Wang W (2006) Reverse correlation between ankle-brachial index and left ventricular mass in patients on maintenance haemodialysis. Nephrology (Carlton) 11:9–14.

33. Roman MJ, Ganau A, Pini R, Pickering TG, et al. (2000) Impact of arterial stiffening on left ventricular structure. Hypertension 36:489–494.

34. Roman MJ, Ganau A, Saba PS, Pini R, Pickering TG, et al. (2000) Impact of arterial stiffening on left ventricular structure. Hypertension 36:489–494.

35. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB (1995) Association of carotid atherosclerosis and left ventricular hypertrophy. J Am Coll Cardiol 23:85–90.

36. Chen SC, Chang JM, Liu WC, Chen YY, Chen LI, et al. (2012) The ratio of noninvasive brachial-ankle pulse wave velocity to measure arterial stiffness: Cross sectional and longitudinal studies. Atherosclerosis 220:488–492.

37. Nardi E, Palermo A, Mule G (2012) Inappropriately high left ventricular mass: Marker of very high cardiovascular risk in patients with chronic kidney disease? Hypertens Res [Epub ahead of print].